3T Multiparametric Magnetic Resonance Imaging-Guided High-Dose Salvage Radiotherapy in Prostate Cancer

dc.contributor.authorCouñago Lorenzo, Felipe
dc.contributor.authorCerro Peñalver, Elia del
dc.contributor.authorOrtiz, I.
dc.contributor.authorDíaz Gavela, Ana Aurora
dc.contributor.authorMarcos, Francisco José
dc.contributor.authorRecio Rodríguez, Manuel
dc.contributor.authorSanz Rosa, David
dc.contributor.authorThuissard Vasallo, Israel John
dc.contributor.authorGonzález, F.
dc.contributor.authorRodríguez Luna, José Manuel
dc.contributor.authorEt al.
dc.date.accessioned2019-11-07T18:22:54Z
dc.date.available2019-11-07T18:22:54Z
dc.date.issued2017
dc.description.abstractPurpose/Objective(s) To analyze the efficacy and toxicity of high-dose salvage intensity-modulated radiotherapy (IMRT) in patients with tumor pelvic recurrence detected by 3T multiparametric magnetic resonance imaging (mpMRI). Materials/Methods Between 2009 and 2014, 55 consecutive patients with biochemical recurrence of prostate cancer after radical prostatectomy who were considered for salvage IMRT were included. mpMRI was carried out in all patients before treatment. Salvage IMRT doses were escalated on macroscopic recurrence detected by mpMRI. Biochemical failure after IMRT was defined using PSA nadir plus 0.2 ng/mL definition. Treatment-related complications were evaluated using Common Terminology Criteria for Adverse Events (CTCAE v4.03). Results mpMRI was positive in 19/55 (34.5%) patients. Local recurrence and pelvic lymph node and bone metastases were found in 13, 4 and 2 patients respectively. Median pre-IMRT PSA was 0.4 ng/mL (interquartile range 0.30–1.93 ng/mL). Patients with a positive mpMRI showed PSA level significantly higher compared to those with a negative mpMRI (0.4 [0.4] vs 2.2 [4.1] ng/mL, p=0.003). Median doses of IMRT in patients with negative and positive mpMRI were 70 (64-74) vs 76 (64-80) Gy, respectively. Seventeen patients (31.5%) received androgen-deprivation therapy as a component of their salvage treatment and eight of these had positive MRI. The mean follow-up was 41 months (range 6-81 months). The 3-year cancer specific survival was 98% (95%CI 94.1-100%) and overall survival was 92.5% (95%CI 85.3-99.6%). Global 3-year biochemical disease-free survival (bDFS) was 82.3% (95%CI 71.7-92.9%). In patients with a negative and positive mpMRI, the 3-year bDFS was similar (82.3% vs 82.5%). The 3-year incidence of grade ≥ 2 rectal and urinary late toxicity was 1.9 % and 14.8 %, respectively. The late grade ≥2 toxicity was resolved without sequelae in 8 of these 9 patients. Conclusion High-dose salvage IMRT on macroscopic mpMRI recurrence was an effective and safe treatment. High doses salvage radiation could explain the good biochemical control observed in patients with high PSA levels and positive mpMRI.spa
dc.description.filiationUEMspa
dc.description.impact5.554 JCR (2017) Q1, 11/129 Radiology, Nuclear Medicine & Medical Imaging, 41/223 Oncologyspa
dc.description.sponsorshipSin financiaciónspa
dc.identifier.citationCounago, F., del Cerro, E., Ortiz, I., Diaz-Gavela, A. A., Marcos, F. J., Recio, M., ... & Castro, J. (2017). 3T Multiparametric Magnetic Resonance Imaging-Guided High-Dose Salvage Radiotherapy in Prostate Cancer. International Journal of Radiation Oncology• Biology• Physics, 99(2), E224-E225. https://doi.org/10.1016/j.ijrobp.2017.06.1140spa
dc.identifier.doi10.1016/j.ijrobp.2017.06.1140
dc.identifier.issn0360-3016
dc.identifier.urihttp://hdl.handle.net/11268/8390
dc.language.isoengspa
dc.peerreviewedSispa
dc.relation.publisherversionhttps://doi.org/10.1016/j.ijrobp.2017.06.1140spa
dc.rights.accessRightsopen accessspa
dc.subject.uemOncologíaspa
dc.subject.uemPróstataspa
dc.subject.uemRadioterapiaspa
dc.subject.unescoCáncerspa
dc.subject.unescoMedicina preventivaspa
dc.title3T Multiparametric Magnetic Resonance Imaging-Guided High-Dose Salvage Radiotherapy in Prostate Cancerspa
dc.typeconference posterspa
dspace.entity.typePublication
relation.isAuthorOfPublication2e374c15-a9f7-4137-99a8-6be419e2c462
relation.isAuthorOfPublicationfd0c5666-6d96-4257-8ffe-b694a2c8b72e
relation.isAuthorOfPublicationef5ebf29-3293-4e06-9d65-92ad1a893322
relation.isAuthorOfPublication3d446e00-e2d3-4c59-837c-f6f25641e481
relation.isAuthorOfPublication9d1f9950-077f-4566-9a9d-b15d6c626060
relation.isAuthorOfPublication6ec266f2-8e29-4c5c-be70-5f0a58f67db8
relation.isAuthorOfPublication770383ba-294c-448b-b800-cd22cbf9fc88
relation.isAuthorOfPublication.latestForDiscovery2e374c15-a9f7-4137-99a8-6be419e2c462

Files